Bevyxxa (betrixaban; Portola Pharmaceuticals) is approved in the US for the prophylaxis of VTE in adult patients hospitalized for an acute medical illness. It is currently the only anticoagulant approved for extended use in both hospital and out-patient settings. The medication is an oral, once-daily factor Xa inhibitor. By directly inhibiting factor Xa, Bevyxxa reduces thrombin generation, thrombus formation, and thrombin-induced platelet aggregation, thus preventing blood clots.
LIST OF FIGURES
7 Figure 1: Bevyxxa for venous thromboembolism – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary of Bevyxxa for venous thromboembolism
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of Bevyxxa for venous thromboembolism
LIST OF TABLES
5 Table 1: Bevyxxa drug profile
6 Table 2: Bevyxxa pivotal trial data in venous thromboembolism
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.